Ryusuke Murakami

17PUBLICATIONS

59CO-AUTHORS

Tumour immunologyPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Pacific Peoples sport and physical activityMedical infection agents (incl. prions)

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (17)

Sort by Publication Date:

|Jul 10, 2026

AI-Based Analysis of Tumor-Infiltrating Lymphocytes and Homologous Recombination in Ovarian Cancer: JGOG3025-A1 Study.

|May 22, 2026

Distinct clinical and prognostic features of cervical adenosquamous carcinoma: a nationwide registry-based and propensity score-matched analysis.

|Mar 12, 2026

A novel CDK12 inhibitor induces homologous recombination deficiency to enhance PARP inhibitor efficacy in uterine serous carcinoma.

Shunsuke Kawahara, Mana Taki, Junzo Hamanishi

|Jan 27, 2026

Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial.

Ryusuke Murakami, Junzo Hamanishi, J B Brown

|Jul 08, 2025

Low-dose oral cyclophosphamide with or without bevacizumab treatment in patients with recurrent ovarian and cervical cancer before best supportive care.

Yusuke Kawaguchi, Ryusuke Murakami, Akihiro Yanai

|Dec 27, 2024

Changes in Physical Activity Across Cancer Diagnosis and Treatment Based on Smartphone Step Count Data Linked to a Japanese Claims Database: Retrospective Cohort Study.

Yoshihide Inayama, Ken Yamaguchi, Kayoko Mizuno

Pageof 3

Frequent Collaborators

Junzo Hamanishi

Masaki Mandai

Koji Yamanoi

Mana Taki

Noriomi Matsumura

Ken Yamaguchi

Taito Miyamoto

Tsukasa Baba

Kaoru Abiko

Kohei Hamada

Frequent Collaborators

Junzo Hamanishi

Masaki Mandai

Koji Yamanoi

Mana Taki